Replimune Group, Inc.
HealthcareNASDAQ:REPL · NASDAQ Global Select
+$0.26 today
Vol 1.96M · Avg 7.45M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-59.5%
avg -11.9%
ROIC
-53.1%
avg -33.4%
ROA
-44.9%
avg -29.2%
Analysis
ROA is currently the strongest return metric at -44.9% versus its period average of -29.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sushil Patel | Chief Executive Officer & Director | $1.06M | — | 55 | $747,492.00 | 0.91% |
Philip Astley-Sparke | Executive Chairman | $960,520.00 | — | 55 | $1.41M | 1.71% |
Konstantinos Xynos | Chief Medical Officer | $781,936.00 | — | 60 | $235,662.00 | 0.29% |
Emily Luisa Hill | Chief Financial Officer | $752,024.00 | — | 46 | $236,556.00 | 0.29% |
Christopher Sarchi | Chief Commercial Officer | $594,578.00 | — | 55 | $180,962.00 | 0.22% |
Camilo Garcia | Chief Human Resource Officer | — | — | — | — | — |
Andrew Schwendenman | Chief Accounting Officer & Treasurer | — | — | 50 | $107,057.00 | 0.13% |
Paul Bullock | Chief Manufacturing Officer & Framingham Site Head | — | — | — | — | — |
Shawn Glidden | Senior Vice President & General Counsel | — | — | — | — | — |
Carolyn Trott | Senior Vice President of Quality Assurance | — | — | — | — | — |
Nina Aragam | Senior Vice President of Portfolio Strategy & Program Management | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
13
$943,856.06
Net Sentiment
$943,856.06
Net selling
Most Active
Sarchi Christopher
4 transactions
1–10 of 13
Analysis
Insiders reported 0 buys worth $0.00 and 13 sells worth $943,856.06 over the last 12 months. That adds up to net selling of $943,856.06. Sarchi Christopher was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.46B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Astria Therapeutics, Inc.
ATXS
$718.13M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$515.41M
Valneva SE
NASDAQ:VALN
$507.78M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
Arvinas, Inc.
NASDAQ:ARVN
$489.07M
Who manages REPL?
Replimune Group, Inc. (REPL) lists 11 active executives. The top listed executive is Sushil Patel, Chief Executive Officer & Director.
Are REPL insiders buying or selling?
Recent insider activity shows net buying of $30.41M.
Explore More
Continue the stock analysis
Jump to another research area for this company.